Skip to main content
SpringerLink
Log in

Epigenetic miRNA Mediated Regulation of RAS in Cardiovascular Diseases

  • Chapter
  • First Online:
The Renin Angiotensin System in Cardiovascular Disease

Part of the book series: Advances in Biochemistry in Health and Disease ((ABHD,volume 24))

  • 486 Accesses

Abstract

The renin angiotensin system (RAS) is well-known for its function in blood pressure regulation and its association with numerous cardiovascular diseases (CVDs). Dysregulation of the RAS can result in hypertension, subsequently promoting cardiovascular disorders, including hypertrophy, cardiac fibrosis, and heart failure. During the Coronavirus disease 2019 (COVID-19) pandemic, further functions of the RAS came to attention, as it was associated with the viral entry. Moreover, the RAS has always been of great research interest due to its importance in physiology. Advances in research have revealed that in addition to the canonical RAS, several organs, for instance, the heart, appear to have their own local RAS. Furthermore, technical advances have led to the discovery of new RAS components and a greater understanding of their interactions and epigenetic regulation. Several mechanisms are associated with epigenetics, including histone modification, DNA methylation, and non-coding RNAs (ncRNAs) such as microRNAs (miRNAs). The role of epigenetic modifications and miRNAs has been of great research interest since miRNAs and their possible functions were discovered. In addition to established laboratory methods, new methods such as next-generation sequencing and bioinformatics provide the necessary tools for finding novel miRNAs with therapeutic value as biomarkers of disease or potential medication. Thus, we aim to give a brief overview of RAS-related miRNAs and their impact on CVDs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Khajehpour S, Aghazadeh-Habashi A (2021) Targeting the protective arm of the renin-angiotensin system: focused on angiotensin-(1–7). J Pharmacol Exp Ther 377(1):64–74

    Article  Google Scholar 

  2. Nehme A, Cerutti C, Dhaouadi N et al (2015) Atlas of tissue renin-angiotensin-aldosterone system in human: a transcriptomic meta-analysis. Sci Rep 5:10035

    Article  Google Scholar 

  3. Nehme A, Zouein FA, Zayeri ZD, Zibara K (2019) An update on the tissue renin angiotensin system and its role in physiology and pathology. J Cardiovasc Dev Dis 6(2)

    Google Scholar 

  4. Mascolo A, Scavone C, Rafaniello C et al (2021) The role of renin-angiotensin-aldosterone system in the heart and lung: focus on COVID-19. Front Pharmacol 12:667254

    Article  CAS  Google Scholar 

  5. Ekholm M, Kahan T (2021) The impact of the renin-angiotensin-aldosterone system on inflammation, coagulation, and atherothrombotic complications, and to aggravated COVID-19. Front Pharmacol 12:640185

    Article  CAS  Google Scholar 

  6. Bader M, Alenina N, Young D et al (2018) The meaning of mas. Hypertension 72(5):1072–1075

    Article  CAS  Google Scholar 

  7. Shu Z, Wan J, Read RJ et al (2021) Angiotensinogen and the modulation of blood pressure. Front Cardiovasc Med 8:645123

    Article  CAS  Google Scholar 

  8. Sequeira-Lopez MLS, Gomez RA (2021) Renin cells, the kidney, and hypertension. Circ Res 128(7):887–907

    Article  CAS  Google Scholar 

  9. Santos RAS, Oudit GY, Verano-Braga T et al (2019) The renin-angiotensin system: going beyond the classical paradigms. Am J Physiol Heart Circ Physiol 316(5):H958–H970

    Article  Google Scholar 

  10. Trask AJ, Ferrario MC (2018) In: Ajay K, Singh GHW (eds) Textbook of nephro-endocrinology, 2nd edn. Academic Press, pp 43–55

    Google Scholar 

  11. Carey RM, Padia SH (2018) In: Ajay K. Singh GHW (eds). Textbook of nephro-endocrinology, 2nd edn. Academic Press, pp 1–25

    Google Scholar 

  12. Ames MK, Atkins CE, Pitt B (2019) The renin-angiotensin-aldosterone system and its suppression. J Vet Intern Med 33(2):363–382

    Article  Google Scholar 

  13. Pugliese NR, Masi S, Taddei S (2020) The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure. Heart Fail Rev 25(1):31–42

    Article  CAS  Google Scholar 

  14. Cavalli G, Heard E (2019) Advances in epigenetics link genetics to the environment and disease. Nature 571(7766):489–499

    Article  CAS  Google Scholar 

  15. Dor Y, Cedar H (2018) Principles of DNA methylation and their implications for biology and medicine. Lancet 392(10149):777–786

    Article  CAS  Google Scholar 

  16. Dangwal S, Schimmel K, Foinquinos A et al (2017). In: Bauersachs J, Butler J, Sandner P (eds) Heart failure. Springer International Publishing, Cham, pp 423–445

    Google Scholar 

  17. Bannister AJ, Kouzarides T (2011) Regulation of chromatin by histone modifications. Cell Res 21(3):381–395

    Article  CAS  Google Scholar 

  18. Liang M (2018) Epigenetic mechanisms and hypertension. Hypertension 72(6):1244–1254

    Google Scholar 

  19. Gerardo-Aviles J, Allen S, Kehoe PG (2017) In: Tolekova AN (eds) Renin-angiotensin system—past, present and future. IntechOpen, London

    Google Scholar 

  20. Paz Ocaranza M, Riquelme JA, García L et al (2020) Counter-regulatory renin–angiotensin system in cardiovascular disease. Nat Rev Cardiol 17(2):116–129

    Article  Google Scholar 

  21. Beermann J, Piccoli M-T, Viereck J, Thum T (2016) Non-coding RNAs in development and disease: background, mechanisms, and therapeutic approaches. Physiol Rev 96(4):1297–1325

    Article  CAS  Google Scholar 

  22. Dangwal S, Thum T (2014) microRNA therapeutics in cardiovascular disease models. Annu Rev Pharmacol Toxicol 54(1):185–203

    Article  CAS  Google Scholar 

  23. Blanco-Domínguez R, Sánchez-Díaz R, de la Fuente H et al (2021) A novel circulating microRNA for the detection of acute myocarditis. N Engl J Med 384(21):2014–2027

    Article  Google Scholar 

  24. Rupaimoole R, Slack FJ (2017) MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discovery 16(3):203–222

    Article  CAS  Google Scholar 

  25. Watanabe K, Narumi T, Watanabe T et al (2020) The association between microRNA-21 and hypertension-induced cardiac remodeling. PLoS ONE 15(2):e0226053

    Article  CAS  Google Scholar 

  26. Improta Caria AC, Nonaka CKV, Pereira CS et al (2018) Exercise training-induced changes in microRNAs: beneficial regulatory effects in hypertension, type 2 diabetes, and obesity. Int J Mol Sci 19(11):3608

    Article  Google Scholar 

  27. Jackson KL, Gueguen C, Lim K et al (2020) Neural suppression of miRNA-181a in the kidney elevates renin expression and exacerbates hypertension in Schlager mice. Hypertens Res 43(11):1152–1164

    Article  CAS  Google Scholar 

  28. Chu HT, Li L, Jia M et al (2020) Correlation between serum microRNA-136 levels and RAAS biochemical markers in patients with essential hypertension. Eur Rev Med Pharmacol Sci 24(22):11761–11767

    Google Scholar 

  29. Lambert Daniel W, Lambert Louise A, Clarke Nicola E et al (2014) Angiotensin-converting enzyme 2 is subject to post-transcriptional regulation by miR-421. Clin Sci 127(4):243–249

    Article  CAS  Google Scholar 

  30. Chen L-J, Xu R, Yu H-M et al (2015) The ACE2/apelin signaling, microRNAs, and hypertension. Int J Hypertens 2015:896861

    Article  Google Scholar 

  31. Kemp JR, Unal H, Desnoyer R et al (2014) Angiotensin II-regulated microRNA 483–3p directly targets multiple components of the renin–angiotensin system. J Mol Cell Cardiol 75:25–39

    Article  CAS  Google Scholar 

  32. Clark AL, Maruyama S, Sano S et al (2016) miR-410 and miR-495 are dynamically regulated in diverse cardiomyopathies and their inhibition attenuates pathological hypertrophy. PLoS ONE 11(3):e0151515

    Article  Google Scholar 

  33. Sotomayor-Flores C, Rivera-Mejías P, Vásquez-Trincado C et al (2020) Angiotensin-(1–9) prevents cardiomyocyte hypertrophy by controlling mitochondrial dynamics via miR-129-3p/PKIA pathway. Cell Death Differ 27(9):2586–2604

    Article  CAS  Google Scholar 

  34. Jeppesen PL, Christensen GL, Schneider M et al (2011) Angiotensin II type 1 receptor signalling regulates microRNA differentially in cardiac fibroblasts and myocytes. Br J Pharmacol 164(2):394–404

    Article  CAS  Google Scholar 

  35. Cao X, Zhang Z, Wang Y et al (2021) MiR-27a-3p/Hoxa10 axis regulates angiotensin II-induced cardiomyocyte hypertrophy by targeting Kv4.3 expression. Front Pharmacol 12

    Google Scholar 

  36. Wang Y, Cai H, Li H et al (2018) Atrial overexpression of microRNA-27b attenuates angiotensin II-induced atrial fibrosis and fibrillation by targeting ALK5. Hum Cell 31(3):251–260

    Article  CAS  Google Scholar 

  37. Hu B, Song J, Qu H et al (2014) Mechanical stretch suppresses microRNA-145 expression by activating extracellular signal-regulated kinase 1/2 and upregulating angiotensin-converting enzyme to alter vascular smooth muscle cell phenotype. PLOS ONE 9(5):e96338

    Google Scholar 

  38. Zhang W, Wang Q, Feng Y et al (2020) MicroRNA-26a protects the heart against hypertension-induced myocardial fibrosis. J Am Heart Assoc 9(18):e017970

    Article  CAS  Google Scholar 

  39. Montgomery RL, Yu G, Latimer PA et al (2014) MicroRNA mimicry blocks pulmonary fibrosis. EMBO Mol Med 6(10):1347–1356

    Article  CAS  Google Scholar 

  40. Huang Y, Tang S, Huang C et al (2017) Circulating miRNA29 family expression levels in patients with essential hypertension as potential markers for left ventricular hypertrophy. Clin Exp Hypertens 39(2):119–125

    Article  CAS  Google Scholar 

  41. Yao SY, Liu J, Li Y et al (2019) Association between plasma microRNA-29a and left ventricular hypertrophy in patients with hypertension. Zhonghua Xin Xue Guan Bing Za Zhi 47(3):215–220

    CAS  Google Scholar 

  42. Abonnenc M, Nabeebaccus AA, Mayr U et al (2013) Extracellular matrix secretion by cardiac fibroblasts: role of microRNA-29b and microRNA-30c. Circ Res 113(10):1138–1147

    Article  CAS  Google Scholar 

  43. Wang X, Wang HX, Li YL et al (2015) MicroRNA Let-7i negatively regulates cardiac inflammation and fibrosis. Hypertension 66(4):776–785

    Article  CAS  Google Scholar 

  44. Eskildsen TV, Jeppesen PL, Schneider M et al (2013) Angiotensin II regulates microRNA-132/-212 in hypertensive rats and humans. Int J Mol Sci 14(6):11190–11207

    Article  Google Scholar 

  45. Eskildsen TV, Schneider M, Sandberg MB et al (2014) The microRNA-132/212 family fine-tunes multiple targets in angiotensin II signalling in cardiac fibroblasts. J Renin-Angiotensin-Aldosterone Syst 16(4):1288–1297

    Google Scholar 

  46. Wei Y, Yan X, Yan L et al (2017) Inhibition of microRNA-155 ameliorates cardiac fibrosis in the process of angiotensin II-induced cardiac remodeling. Mol Med Rep 16(5):7287–7296

    Article  CAS  Google Scholar 

  47. Yang Y, Zhou Y, Cao Z et al (2016) miR-155 functions downstream of angiotensin II receptor subtype 1 and calcineurin to regulate cardiac hypertrophy. Exp Ther Med 12(3):1556–1562

    Article  CAS  Google Scholar 

  48. Ceolotto G, Papparella I, Bortoluzzi A et al (2011) Interplay between miR-155, AT1R A1166C polymorphism, and AT1R expression in young untreated hypertensives. Am J Hypertens 24(2):241–246

    Article  CAS  Google Scholar 

  49. Thum T, Gross C, Fiedler J et al (2008) MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456(7224):980–984

    Article  CAS  Google Scholar 

  50. Alavi-Moghaddam M, Chehrazi M, Alipoor SD et al (2018) A Preliminary study of microRNA-208b after acute myocardial infarction: impact on 6-month survival. Dis Markers 2018:2410451

    Article  Google Scholar 

  51. Montgomery RL, Hullinger TG, Semus HM et al (2011) Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 124(14):1537–1547

    Article  CAS  Google Scholar 

  52. Sharma NM, Nandi SS, Zheng H et al (2017) A novel role for miR-133a in centrally mediated activation of the renin-angiotensin system in congestive heart failure. Am J Physiol-Heart Circulatory Physiol 312(5):H968–H979

    Article  Google Scholar 

  53. Chen C-Y, Lee DS, Choong OK et al (2021) Cardiac-specific microRNA-125b deficiency induces perinatal death and cardiac hypertrophy. Sci Rep 11(1):2377

    Article  CAS  Google Scholar 

  54. Jiang X, Ning Q, Wang J (2013) Angiotensin II induced differentially expressed microRNAs in adult rat cardiac fibroblasts. J Physiol Sci 63(1):31–38

    Article  CAS  Google Scholar 

  55. Nagpal V, Rai R, Place AT et al (2016) MiR-125b is critical for fibroblast-to-myofibroblast transition and cardiac fibrosis. Circulation 133(3):291–301

    Article  CAS  Google Scholar 

  56. Liu ZY, Lu M, Liu J et al (2020) MicroRNA-144 regulates angiotensin II-induced cardiac fibroblast activation by targeting CREB. Exp Ther Med 20(3):2113–2121

    CAS  Google Scholar 

  57. Zhou Y, Deng L, Zhao D et al (2016) MicroRNA-503 promotes angiotensin II-induced cardiac fibrosis by targeting apelin-13. J Cell Mol Med 20(3):495–505

    Article  CAS  Google Scholar 

  58. Chen K, Zhao X-L, Li L-B et al (2020) miR-503/apelin-12 mediates high glucose-induced microvascular endothelial cells injury via JNK and p38MAPK signaling pathway. Regenerative Therapy 14:111–118

    Article  Google Scholar 

  59. Hong Y, Cao H, Wang Q et al (2016) MiR-22 may suppress fibrogenesis by targeting TGFβR I in cardiac fibroblasts. Cell Physiol Biochem 40(6):1345–1353

    Article  CAS  Google Scholar 

  60. Hoeper MM, McLaughlin VV, Dalaan AMA et al (2016) Treatment of pulmonary hypertension. Lancet Respir Med 4(4):323–336

    Article  CAS  Google Scholar 

  61. Wilkins MR (2012) Pulmonary hypertension: the science behind the disease spectrum. Eur Respir Rev 21(123):19

    Article  CAS  Google Scholar 

  62. Improta-Caria AC, Aras MG, Nascimento L et al (2021) MicroRNAs regulating renin–angiotensin–aldosterone system, sympathetic nervous system and left ventricular hypertrophy in systemic arterial hypertension. Biomolecules 11(12):1771

    Article  CAS  Google Scholar 

  63. Oparil S, Acelajado MC, Bakris GL et al (2018) Hypertension. Nat Rev Dis Primers 4(1):18014

    Article  Google Scholar 

  64. Shenasa M, Shenasa H (2017) Hypertension, left ventricular hypertrophy, and sudden cardiac death. Int J Cardiol 237:60–63

    Article  Google Scholar 

  65. Cacciapuoti F (2011) Molecular mechanisms of left ventricular hypertrophy (LVH) in systemic hypertension (SH)—possible therapeutic perspectives. J Am Soc Hypertens 5(6):449–455

    Article  CAS  Google Scholar 

  66. Frieler RA, Mortensen RM (2015) Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling. Circulation 131(11):1019–1030

    Article  Google Scholar 

  67. Boettger T, Beetz N, Kostin S et al (2009) Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Investig 119(9):2634–2647

    Article  CAS  Google Scholar 

  68. Chen C, Ponnusamy M, Liu C et al (2017) MicroRNA as a therapeutic target in cardiac remodeling. Biomed Res Int 2017:1278436

    Article  Google Scholar 

  69. Frey N, Katus HA, Olson EN, Hill JA (2004) Hypertrophy of the heart. Circulation 109(13):1580–1589

    Article  Google Scholar 

  70. Díaz HS, Toledo C, Andrade DC et al (2020) Neuroinflammation in heart failure: new insights for an old disease. J Physiol 598(1):33–59

    Article  Google Scholar 

  71. Adamcova M, Kawano I, Simko F (2021) The impact of microRNAs in renin–angiotensin-system-induced cardiac remodelling. Int J Mol Sci 22(9):4762

    Article  CAS  Google Scholar 

  72. Eissa MG, Artlett CM (2019) The microRNA miR-155 is essential in fibrosis. Noncoding RNA 5(1)

    Google Scholar 

  73. Wang Y, Tan J, Wang L et al (2021) MiR-125 family in cardiovascular and cerebrovascular diseases. Front Cell Dev Biol 9

    Google Scholar 

  74. Travers JG, Kamal FA, Robbins J et al (2016) Cardiac fibrosis. Circ Res 118(6):1021–1040

    Article  CAS  Google Scholar 

  75. Castoldi G, di Gioia CRT, Bombardi C et al (2012) MiR-133a regulates collagen 1A1: potential role of miR-133a in myocardial fibrosis in angiotensin II-dependent hypertension. J Cell Physiol 227(2):850–856

    Article  CAS  Google Scholar 

  76. Carè A, Catalucci D, Felicetti F et al (2007) MicroRNA-133 controls cardiac hypertrophy. Nat Med 13(5):613–618

    Article  Google Scholar 

  77. Chen J-F, Mandel EM, Thomson JM et al (2006) The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 38(2):228–233

    Article  CAS  Google Scholar 

  78. Angelini A, Li Z, Mericskay M, Decaux J-F (2015) Regulation of connective tissue growth factor and cardiac fibrosis by an SRF/microRNA-133a axis. PLoS ONE 10(10):e0139858

    Article  Google Scholar 

  79. Duisters RF, Tijsen AJ, Schroen B et al (2009) miR-133 and miR-30 regulate connective tissue growth factor. Circ Res 104(2):170–178

    Article  CAS  Google Scholar 

  80. Lipson KE, Wong C, Teng Y, Spong S (2012) CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair 5(1):S24

    Article  Google Scholar 

  81. Song J-J, Yang M, Liu Y et al (2020) MicroRNA-122 aggravates angiotensin II-mediated apoptosis and autophagy imbalance in rat aortic adventitial fibroblasts via the modulation of SIRT6-elabela-ACE2 signaling. Eur J Pharmacol 883:173374

    Article  CAS  Google Scholar 

  82. He Y, Cai Y, Pai PM et al (2021) The causes and consequences of miR-503 dysregulation and its impact on cardiovascular disease and cancer. Front Pharmacol 12

    Google Scholar 

  83. Zhou H, Tang W, Yang J et al (2021) MicroRNA-related strategies to improve cardiac function in heart failure. Front Cardiovasc Med 8

    Google Scholar 

  84. Mozaffarian D, Benjamin EJ, Go AS et al (2016) Heart disease and stroke statistics—2016 update. Circulation 133(4):e38–e360

    Google Scholar 

  85. Patel VB, Zhong J-C, Grant MB, Oudit GY (2016) Role of the ACE2/angiotensin 1–7 axis of the renin-angiotensin system in heart failure. Circ Res 118(8):1313–1326

    Article  CAS  Google Scholar 

  86. Hinkel R, Batkai S, Bähr A et al (2021) AntimiR-132 attenuates myocardial hypertrophy in an animal model of percutaneous aortic constriction. J Am Coll Cardiol 77(23):2923–2935

    Article  CAS  Google Scholar 

  87. Seok HY, Chen J, Kataoka M et al (2014) Loss of microRNA-155 protects the heart from pathological cardiac hypertrophy. Circ Res 114(10):1585–1595

    Article  CAS  Google Scholar 

  88. Akerman AW, Blanding WM, Stroud RE et al (2019) Elevated wall tension leads to reduced miR-133a in the thoracic aorta by exosome release. J Am Heart Assoc 8(1):e010332

    Article  CAS  Google Scholar 

  89. Huang C, Wang Y, Li X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223):497–506

    Article  CAS  Google Scholar 

  90. Gandhi RT, Lynch JB, del Rio C (2020) Mild or moderate Covid-19. N Engl J Med 383(18):1757–1766

    Article  CAS  Google Scholar 

  91. Nishiga M, Wang DW, Han Y et al (2020) COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol 17(9):543–558

    Article  CAS  Google Scholar 

  92. Satterfield BA, Bhatt DL, Gersh BJ (2021) Publisher correction: cardiac involvement in the long-term implications of COVID-19. Nat Rev Cardiol

    Google Scholar 

  93. Cooper SL, Boyle E, Jefferson SR et al (2021) Role of the Renin–angiotensin–aldosterone and kinin-kallikrein systems in the cardiovascular complications of COVID-19 and long COVID. Int J Mol Sci 22(15):8255

    Article  CAS  Google Scholar 

  94. Lu R, Zhao X, Li J et al (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395(10224):565–574

    Article  CAS  Google Scholar 

  95. Tajbakhsh A, Gheibi Hayat SM, Taghizadeh H et al (2021) COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up. Expert Rev Anti Infect Ther 19(3):345–357

    Article  CAS  Google Scholar 

  96. Rath S, Perikala V, Jena AB, Dandapat J (2021) Factors regulating dynamics of angiotensin-converting enzyme-2 (ACE2), the gateway of SARS-CoV-2: epigenetic modifications and therapeutic interventions by epidrugs. Biomed Pharmacother 143:112095

    Article  CAS  Google Scholar 

  97. Garg A, Seeliger B, Derda AA et al (2021) Circulating cardiovascular microRNAs in critically ill COVID-19 patients. Eur J Heart Fail 23(3):468–475

    Article  CAS  Google Scholar 

  98. Mahmudpour M, Roozbeh J, Keshavarz M et al (2020) COVID-19 cytokine storm: the anger of inflammation. Cytokine 133:155151

    Article  CAS  Google Scholar 

  99. Kotchen TA (2011) Historical trends and milestones in hypertension research. Hypertension 58(4):522–538

    Article  CAS  Google Scholar 

  100. Satoh M, Takahashi Y, Tabuchi T et al (2014) Circulating toll-like receptor 4-responsive microRNA panel in patients with coronary artery disease: results from prospective and randomized study of treatment with renin–angiotensin system blockade. Clin Sci 128(8):483–491

    Article  Google Scholar 

  101. Crackower MA, Sarao R, Oudit GY et al (2002) Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417(6891):822–828

    Article  CAS  Google Scholar 

  102. Hernández Prada JA, Ferreira AJ, Katovich MJ et al (2008) Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 51(5):1312–1317

    Article  Google Scholar 

  103. Rathinasabapathy A, Bryant AJ, Suzuki T et al (2018) rhACE2 therapy modifies bleomycin-induced pulmonary hypertension via rescue of vascular remodeling. Front Physiol 9

    Google Scholar 

  104. Ramchand J, Burrell LM (2020) Circulating ACE2: a novel biomarker of cardiovascular risk. Lancet 396(10256):937–939

    Article  CAS  Google Scholar 

  105. Ferrario CM, Martell N, Yunis C et al (1998) Characterization of angiotensin-(1–7) in the urine of normal and essential hypertensive subjects*. Am J Hypertens 11(2):137–146

    Article  CAS  Google Scholar 

  106. Soltani Hekmat A, Javanmardi K, Kouhpayeh A et al (2017) Differences in cardiovascular responses to alamandine in two-kidney, one clip hypertensive and normotensive rats. Circ J 81(3):405–412

    Article  Google Scholar 

  107. Schindler C, Bramlage P, Kirch W, Ferrario CM (2007) Role of the vasodilator peptide angiotensin-(1–7) in cardiovascular drug therapy. Vasc Health Risk Manag 3(1):125–137

    CAS  Google Scholar 

  108. Regional Health—Europe TL (2021) Pandemic heightens the need to combat cardiovascular diseases. Lancet Reg Health Europe 8

    Google Scholar 

  109. Bauer A, Schreinlechner M, Sappler N et al (2021) Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial. Lancet Respir Med 9(8):863–872

    Article  CAS  Google Scholar 

  110. Kerneis M, Montalescot G (2021) RAS inhibition and COVID-19: more questions than answers? Lancet Respir Med 9(8):807–809

    Article  CAS  Google Scholar 

  111. Lopes RD, Macedo AVS, de Barros E Silva PGM et al (2021) Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial. JAMA 325(3):254–264

    Google Scholar 

  112. Li J, Wang X, Chen J et al (2020) Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol 5(7):825–830

    Article  Google Scholar 

  113. Baral R, Tsampasian V, Debski M et al (2021) Association between renin-angiotensin-aldosterone system inhibitors and clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA Netw Open 4(3):e213594–e213594

    Article  Google Scholar 

  114. Breitenbach T, Lorenz K, Dandekar T (2019) How to steer and control ERK and the ERK signaling cascade exemplified by looking at cardiac insufficiency. Int J Mol Sci 20(9):2179

    Article  CAS  Google Scholar 

  115. Baker M (2012) Gene data to hit milestone. Nature 487(7407):282–283

    Article  CAS  Google Scholar 

  116. Chen Y, Wang X (2020) miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res 48(D1):D127–D131

    Article  CAS  Google Scholar 

  117. Staessen JA, Wang J, Bianchi G, Birkenhäger WH (2003) Essential hypertension. Lancet 361(9369):1629–1641

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Bioinformatics, Biocenter, University of Würzburg, Würzburg, Germany

    Aylin Caliskan & Samantha A. W. Crouch

  2. Department of Medicine, Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA

    Seema Dangwal

Authors
  1. Aylin Caliskan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samantha A. W. Crouch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Seema Dangwal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Seema Dangwal .

Editor information

Editors and Affiliations

  1. Institute of Cardiovascular Sciences, St. Boniface Hospital, Manitoba, MB, Canada

    Naranjan S. Dhalla

  2. Institute of Cardiovascular Sciences, St. Boniface Hospital, Winnipeg, MB, Canada

    Sukhwinder K. Bhullar

  3. California State University Los Angeles, Los Angeles, CA, USA

    Anureet K. Shah

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Caliskan, A., Crouch, S.A.W., Dangwal, S. (2023). Epigenetic miRNA Mediated Regulation of RAS in Cardiovascular Diseases. In: Dhalla, N.S., Bhullar, S.K., Shah, A.K. (eds) The Renin Angiotensin System in Cardiovascular Disease. Advances in Biochemistry in Health and Disease, vol 24. Springer, Cham. https://doi.org/10.1007/978-3-031-14952-8_5

Download citation

Publish with us

Policies and ethics

Search

Navigation